Corrigendum to: Therapeutics for COVID-19: established and in development

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first recognised in late 2019, with over 30 000 cases and 1 deaths reported the end of September 2020. SARS-CoV-2 infection is usually associated fever, cough, coryza, dyspnoea, anosmia, headache fatigue may cause pneumonia hypoxemia. An excessive/dysregulated inflammatory response lead to lung damage including distress (ARDS), coagulopathy other complications. Mortality amongst hospitalised patients higher those needing intensive care. In Australia 27 882 had been September, most Victoria. Two therapies have proven beneficial treatment expedited randomised placebo-controlled trials are now widespread use. Dexamethasone improved survival requiring support antiviral agent remdesivir decreased time recovery mild-moderate disease. Remdesivir authorised Australian Therapeutic Goods Administration July Over 200 therapeutics being tested for COVID-19 more than 2000 clinical trials, many agents preclinical development. We review evidence some candidates therapy COVID-19.